Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | ATM | Q13315 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | ALPG | P10696 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | MAOB | P27338 | 5/20 | 0.68 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.68 |
| ▸ | BCHE | P06276 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893358 | 1.00 | CYP1B1 (0.69) | CYP1B1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL30266685 | 0.92 | RELA (0.72) | CYP1B1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL16939624 | 0.92 | RELA (0.72) | CYP1B1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL13203572 | 0.92 | CYP1B1 (0.71) | CYP1B1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL2649171 | 0.91 | MAPT (0.67) | CYP1B1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL13776894 | 0.91 | MAPT (0.67) | CYP1B1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL1797521 | 0.90 | P4HB (0.77) | CYP1B1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL5873205 | 0.90 | CYP1B1 (0.68) | CYP1B1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL8735847 | 0.90 | CYP1B1 (0.68) | CYP1B1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL5873207 | 0.90 | CYP1B1 (0.68) | CYP1B1MAPTLMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113072536-B | Method for preparing 2-phenyl-3-benzoyl benzodihydrogen selenium substituted pyridine compound without metal catalysis | 浙江农林大学暨阳学院 | 2021-11-23 | — | — | CN | disclosed |
| CN-113461501-A | Green method for high-selectivity synthesis of chalcone compounds | 温州大学 | 2021-10-01 | — | — | CN | disclosed |
| CN-113072536-A | Method for preparing 2-phenyl-3-benzoyl benzodihydrogen selenium substituted pyridine compound without metal catalysis | 浙江农林大学暨阳学院 | 2021-07-06 | — | — | CN | disclosed |
| US-9085520-B2 | Composition for treating diabetes and metabolic diseases and a preparation method thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2015-07-21 | — | — | US | disclosed |
| US-20140350304-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-11-27 | — | — | US | disclosed |
| EP-2651904-B1 | BISPYRIMIDINES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2014-11-12 | — | — | EP | disclosed |
| EP-2651904-A1 | BISPYRIMIDINES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2013022951-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-02-14 | — | — | WO | disclosed |
| US-8362246-B2 | Bispyrimidines for electronic applications | BASF SE (DE) | 2013-01-29 | — | — | US | disclosed |
| WO-2012080052-A1 | BISPYRIMIDINES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2012-06-21 | — | — | WO | disclosed |
| US-20120149904-A1 | BISPYRIMIDINES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149904-A1 | BISPYRIMIDINES FOR ELECTRONIC APPLICATIONS | DPYD, TYMP, TYMS | CYP1B1 777/4885MAPT 1242/4885LMNA 3854/4885 |
| US-20140350304-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | FABP1, GYS2, CYP7B1 | CYP1B1 174/4885MAPT 4070/4885LMNA 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.